Boehringer Ingelheim Loses Legal Challenge to IRA in Federal Court Ruling

Published: Jul 08, 2024 By Tristan Manalac

Boehringer Ingelheim_iStock, Sundry Photography

Pictured: Boehringer Ingelheim’s headquarters in Silicon Valley/iStock, Sundry Photography

A federal court last week ruled against Boehringer Ingelheim’s legal challenge to the Medicare Drug Price Negotiation Program, granting the Biden administration its latest victory over the pharma industry’s efforts to block the Inflation Reduction Act.

In its lawsuit filed in August 2023, the pharma argued that the negotiation program is voluntary only in name. By leveraging Medicare and Medicaid—which account for around half of the market—the government is essentially forcing the companies to participate in the drug price negotiations.

In a 47-page decision, Judge Michael Shea of the U.S. District Court of Connecticut disagreed with the pharma ruling that companies remain free to withdraw from Medicare or Medicaid and can decide not to participate in the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks